Exagen (XGN) Q1 2026 Earnings Transcript

Exagen reported record Q1 revenue of $17.3 million, up 12% year over year, with gross margin holding at 59% and adjusted EBITDA loss improving 14% to $2.2 million. Trailing-12-month ASP rose 6% to $444, supported by $900,000 in out-of-period collections, while ordering clinicians increased 15% to just over 2,700 and management reaffirmed 2026 revenue guidance of $70 million to $73 million. Weather disruptions reduced Q1 volume, but the company highlighted continued sales force expansion, pharma backlog above $5 million, and a myositis launch targeted for early 2027.

Analysis

The key read-through is that Exagen is starting to look less like a purely reimbursement-beta story and more like a self-help compounder with three reinforcing loops: territory expansion, payer collections, and pipeline credibility. The first two are already feeding each other—new reps broaden the call base, while better reimbursement makes every incremental test more valuable—so the market may be underestimating how much operating leverage can show up if the sales force keeps maturing into the back half of the year.

The biggest near-term swing factor is not volume alone, but the durability of ASP. Management clearly benefited from lumpy prior-period collections this quarter, and that creates a setup where reported momentum can decelerate even if underlying execution remains intact. That matters because the stock will likely trade on quarter-to-quarter ASP optics until there is more evidence that payer mix, appeals, and in-network progress can convert one-time wins into a higher recurring baseline.

The contrarian bull case is that consensus may be too focused on the variability and too dismissive of the optionality. With only a low-single-digit penetration of a multi-billion dollar market, modest share gains can support several years of double-digit revenue growth, while the myositis launch gives the sales force a second product to monetize without a wholesale incremental SG&A step-up. The real tell will be whether revenue growth continues to outrun SG&A through 2H26; if it does, the path to a mid-60s gross margin profile becomes more credible and the equity re-rates on quality of growth rather than just reimbursement noise.

Main risks are timing-based: LCD delays, weather-like disruption to sample flow, and any disappointment from Q2/Q3 ASP normalization. The stock is vulnerable if investors extrapolate Q1 collections into a run-rate and that proves wrong over the next 1-2 quarters. On the other hand, if payer advocacy and the new markers keep pulling through pharma demand, that adds a second engine that can cushion any diagnostic reimbursement volatility.

Key Decisions for Investors

• Initiate a tactical long in XGN over the next 1-3 weeks, but size it as a catalyst trade rather than a core hold; upside is another 15-25% if Q2 shows stable ASP and continued clinician growth, while downside is 10-15% if collections normalize faster than expected.
• For existing XGN longs, buy 3-6 month downside protection via puts or put spreads around the next two earnings cycles; the cleanest risk is an ASP air-pocket, and options are preferable because headline volatility is likely to stay elevated.
• Pair trade: long XGN / short a basket of reimbursement-sensitive diagnostics or small-cap healthcare names with weaker operating leverage; the relative setup favors companies with improving rep productivity and a visible pipeline over names still reliant on one-off reimbursement events.
• Do not chase after a strong Q1 print until there is confirmation of Q2 volume resilience; use any post-earnings compression or ASP skepticism to add, because the best entry is likely when the market starts discounting the lumpy collections narrative.
• Watch ACR as a second-order read-through on payer advocacy and autoimmune diagnostics access; if its advocacy is translating into broader coverage momentum, that is an indirect bullish signal for XGN over the next 6-12 months.